| Basics |
Innoviva, Inc.
Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline.
|
| IPO Date: |
November 25, 2008 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$1.2B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.20 | 1.46%
|
| Avg Daily Range (30 D): |
$0.12 | 0.67%
|
| Avg Daily Range (90 D): |
$0.14 | 0.77%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.64M |
| Avg Daily Volume (30 D): |
.48M |
| Avg Daily Volume (90 D): |
.56M |
| Trade Size |
| Avg Trade Size (Sh.): |
98 |
| Avg Trade Size (Sh.) (30 D): |
53 |
| Avg Trade Size (Sh.) (90 D): |
61 |
| Institutional Trades |
| Total Inst.Trades: |
4,223 |
| Avg Inst. Trade: |
$1.72M |
| Avg Inst. Trade (30 D): |
$2.25M |
| Avg Inst. Trade (90 D): |
$2.53M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$2.32M |
| Avg Closing Trade (90 D): |
$2.65M |
| Avg Closing Volume: |
118.85K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.95
|
$-.74
|
$.32
|
|
Diluted EPS
|
$-.96
|
$-.74
|
$.31
|
|
Revenue
|
$ 369.84M
|
$ 88.63M
|
$ 91.81M
|
|
Gross Profit
|
$
|
$ 73.32M
|
$
|
|
Net Income / Loss
|
$ -59.72M
|
$ -46.58M
|
$ 20.33M
|
|
Operating Income / Loss
|
$ 33.69M
|
$ 41.43M
|
$ 24.69M
|
|
Cost of Revenue
|
$
|
$ 15.32M
|
$
|
|
Net Cash Flow
|
$ 140.73M
|
$ 14.13M
|
$ 44.33M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 17, 2013:
1:100
|
|
